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Tibial post fracture pain is reduced in kinin 
receptors deficient mice and blunted by kinin 
receptor antagonists
Vincent Minville1,2,7* , Lionel Mouledous3, Acil Jaafar4, Réjean Couture5, Anne Brouchet6, Bernard Frances3, 
Ivan Tack2,4 and Jean‑Pierre Girolami2
Abstract 
Background: Tibial fracture is associated with inflammatory reaction leading to severe pain syndrome. Bradykinin 
receptor activation is involved in inflammatory reactions, but has never been investigated in fracture pain.
Methods: This study aims at defining the role of B1 and B2‑kinin receptors (B1R and B2R) in a closed tibial fracture 
pain model by using knockout mice for B1R (B1KO) or B2R (B2KO) and wild‑type (WT) mice treated with antagonists 
for B1R (SSR 240612 and R954) and B2R (HOE140) or vehicle. A cyclooxygenase (COX) inhibitor (ketoprofen) and an 
antagonist (SB366791) of Transient Receptor Potential Vaniloid1 (TRPV1) were also investigated since these path‑
ways are associated with BK‑induced pain in other models. The impact on mechanical and thermal hyperalgesia and 
locomotion was assessed by behavior tests. Gene expression of B1R and B2R and spinal cord expression of c‑Fos were 
measured by RT‑PCR and immunohistochemistry, respectively.
Results: B1KO and B2KO mice demonstrated a reduction in post‑fracture pain sensitivity compared to WT mice that 
was associated with decreased c‑Fos expression in the ipsilateral spinal dorsal horn in B2KO. B1R and B2R mRNA and 
protein levels were markedly enhanced at the fracture site. B1R and B2R antagonists and inhibition of COX and TRPV1 
pathways reduced pain in WT. However, the analgesic effect of the COX‑1/COX‑2 inhibitor disappeared in B1KO and 
B2KO. In contrast, the analgesic effect of the TRPV1 antagonist persisted after gene deletion of either receptor.
Conclusions: It is suggested that B1R and B2R activation contributes significantly to tibial fracture pain through COX. 
Hence, B1R and B2R antagonists appear potential therapeutic agents to manage post fracture pain.
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Background
Tissue damage and inflammation lead to the activation 
of several inflammatory and pain systems among which 
is the kallikrein–kinin system. Kallikreins are proteo-
lytic enzymes, which generate kinins, namely brady-
kinin (BK) and related peptides (Lys-BK) including 
their active metabolites from kininogen substrates [1]. 
The nonapeptide BK is an initial mediator of inflamma-
tion that induces pain [2–5]. The actions of kinins are 
mediated through the activation of two G-protein cou-
pled receptors, B1 and B2. It was first hypothesized that 
the B1 receptor (B1R) is only expressed as a result of 
tissue damage and inflammatory signals whereas the B2 
receptor (B2R) is constitutively expressed [1]. Consist-
ently, B1R and B2R knockout mice showed hypoalge-
sia against inflammatory pain stimuli [6, 7] confirming 
the role of kinin receptors in pain signaling pathways 
in response to tissue damage and inflammation. The 
involvement of kinin receptors in inflammatory and 
neuropathic pain processes is now well recognized and 
extensively reviewed [5, 7]. Signaling relaying kinin 
receptors involves prostanoids and leucotrienes syn-
thesis and sensitization of ion channels, especially the 
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Transient Receptor Potential Vanilloid 1 (TRPV1) and 
Transient Receptor Potential cation channel subfamily 
A or M8 (TRPA1 and TRPM8, respectively) [5, 8, 9].
Several animal pain models exist to assess the effi-
cacy of drugs or to study the physiopathology of pain 
[5]. Recently, we have described a new model of frac-
ture pain in mice [10]. Tibial fracture models were first 
developed in rats [11] and have been used to investi-
gate several systems involved in the so-called Complex 
Regional Pain Syndrome (CRPS) [12]. In human CRPS 
formerly known as Sudeck’s dystrophy is a disabling 
pain syndrome occurring after fractures or lesions of 
the peripheral or Central Nervous System (CNS), which 
is associated with mechanical and thermal hyperalge-
sia and allodynia at the level of the skin. Several physi-
opathological concepts involving various mechanisms 
have been proposed but no clear therapeutic strategy 
has yet emerged thereby justifying further investiga-
tions on animal models. It was first demonstrated that 
substance P signaling contributes to the vascular and 
nociceptive abnormalities in a tibial fracture rat model 
of CRPS [13]. From these studies in rats, it is known 
that anti-nerve growth factor (NGF) antibodies reduced 
some but not all signs characteristic of CRPS, illustrat-
ing the complexity of CRPS pathogenesis and NGF 
signaling [14, 15]. Recently, the same authors reported 
that IL-1beta contributes to chronic regional nocicep-
tive sensitization after fracture, possibly by stimulating 
NGF overexpression in keratinocytes [16–20]. Collec-
tively, these studies support the involvement of inflam-
matory cytokines, including TNF-alpha [14, 15] in the 
nociceptive sensitization after fracture. Moreover, it 
has been proposed that the upregulation of cytokine 
production depends on the activation of multi-protein 
complexes termed inflammasomes, which could be 
involved in the processing and activation of pro-inflam-
matory cytokines [16–20]. However, most of these 
investigations have focused on the chronic signaling 
pathways leading to post-traumatic chronic inflamma-
tion and pain mechanisms rather than on the potential 
upstream targets. In that respect, the kallikrein/kinin 
system could be recruited very early during the acute 
post-fracture pain, a possibility never investigated. For 
instance, pro-inflammatory cytokines are known to 
induce and upregulate B1R through the activation of 
the transcriptional nuclear factor NF-kappaB in several 
experimental models [21–24].
Therefore, the aim of this study was to assess the role 
of B1R and B2R in a model of post fracture pain in kinin 
receptor deficient mice. Moreover, we investigated the 
potential analgesic effect of B1R and B2R antagonists and 
of cyclooxygenase (COX) and TRPV1 receptor inhibitors 
in the mouse fracture model. The results identify B1R 
and B2R as early therapeutic targets in this clinically rel-
evant acute fracture pain model.
Materials and methods
Animals
Animal experimentation was authorized by the French 
Direction of Veterinary Service to J.P.G., L.M., and B.F. 
The study was approved by The French Animal Care 
and Use Committee (Comité régional d’éthique pour 
l’expérimentation animale Midi Pyrénées, ref: MP 
02/02/02/06). Experiments were performed in accord-
ance with the guidelines for the care and use of labora-
tory animals and the ethical guidelines for investigations 
of experimental pain in conscious animals [25], and the 
European Communities Council Directive of November 
24 1986 (86/609/EEC). Maximal efforts have been made 
to minimize the number of animals used and their suf-
fering. Experiments were conducted using male wild-
type (WT) C57 BL/6 mice (Janvier Lab., Le Genest St 
Isle France) and mice deficient for the B1 (B1KO) and 
B2 (B2KO) kinin receptors (C57 BL/6 background). The 
B2KO colony was established in our laboratory from 
genitors kindly donated by Dr. F. Hess (Merck Research 
Laboratory, Princetown, USA), whereas B1KO mice were 
provided by Professor M. Bader (Berlin, Germany). The 
animals were housed in isolator cages with solid floor 
covered with 3  cm of soft bedding and they had free 
access to standard chow diet and tap water. Animals 
were maintained on a 12 h light–dark cycle. The follow-
ing inhibitors were used: B2R antagonist (Icatibant also 
named HOE 140) from Sanofi Aventis (Frankfurt Ger-
many), B1R antagonist (SSR 240612), known to cross the 
blood–brain barrier (BBB), from Sanofi Aventis (Frank-
furt Germany), the B1R antagonist R954, which does not 
pass the BBB was generously provided by Pr F. Gobeil 
Jr (Sherbrooke, Canada). The COX-1/COX-2 inhibitor 
ketoprofen was obtained from Sanofi Aventis (Montpel-
lier, France) and the TRPV1 antagonist SB 366791 was 
purchased from Tocris Bioscience (Minneapolis, USA).
Surgery
Unilateral closed tibial fracture was performed under 
2%-sevoflurane (Abbott, Suresnes France) anesthesia as 
previously described [10]. Briefly, after antiseptic prepa-
ration of the right paw with povidone iodine, a closed 
fracture was produced using a specially designed frac-
ture apparatus (blunt guillotine). Before fracture, an 
intramedullary pinning was performed under sterile 
conditions; a hole was made above the tibial tuberosity 
percutaneously using a 27-gauge needle (BD, Drogheda, 
Ireland). Then the needle was directed into the medul-
lary canal. By rotating the needle, the canal was reamed 
to 5 mm up to the ankle joint. The end of the needle was 
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cut as short as possible so that the skin could roll over 
and cover it. No suture was used. Then, the mouse was 
placed with the leg on the anvil so that the blunt guil-
lotine lined up with the proximal third of the tibia. The 
300 g weight was dropped from a height of 9–10 cm frac-
turing the tibia shaft. Closed fracture was confirmed post 
mortem by examining whether the nail is intra medullary 
or not. Only mice with intra-medullary inserted nail were 
included in the study.
Behavioral assay
Three tests were used to assess pain behavior: (i) Mechan-
ical nociception assessed by the withdrawal response to 
von Frey filament application, (ii) Thermal nociception 
assessed by the withdrawal response to thermal stimulus 
(hot plate test), and (iii) Subjective pain determined using 
a pain rating scale as described by Attal et al. [26].
Mechanical nociception
Unrestrained mice were placed beneath a clear plas-
tic chamber on an elevated mesh floor and allowed to 
acclimate. Withdrawal responses to mechanical stimu-
lation were determined using calibrated von Frey fila-
ments (from 0.008 to 8  g) applied from underneath the 
cage through openings in the plastic mesh floor against 
the hind paw plantar skin at approximately middle of the 
fractured leg. The filament was pushed until it slightly 
bowed and then it was maintained in that position for 6 s. 
Each von Frey filament was applied once starting with 
0.008 g and continuing with higher force filaments until a 
withdrawal response was reached, which was considered 
as a positive response. The test was repeated 3 times. The 
lowest force from the three tests producing a response 
was considered the withdrawal threshold.
Thermal nociception
Thermal nociception was measured by a modified hot-
plate test [27]. The time that a mouse leaves its hind paw 
on a hot plate at 52 °C reflects thermal nociception (ther-
mal latency). The paw was removed from the plate after a 
maximal time of 12 s by the investigator to avoid thermal 
injury and thermal hyperalgesia. This test was repeated 
three times on each hind paw for each mouse.
Subjective pain scale
A subjective pain rating scale (0–5) modified from that 
previously described [28] was used to quantify pain, 
where: 0 is normal, 1 is curling of the toes, 2 is eversion of 
the paw, 3 is partial weight bearing, 4 is non-weight bear-
ing and guarding, and 5 is avoidance with any contact 
with the hind limb.
Locomotors activity: Actimeter
The device  (Apelex®) has five Plexiglas boxes, identical 
dimensions of 25 cm (length) × 21.5 cm (width) × 9.5 cm 
(height). Two beams in each box to address the move-
ment of mouse. All the boxes are cut from light, sound, 
and the external environment. Locomotors activity was 
measured using counters within the number of times 
mice crossed beams. The tests lasted 30  min and were 
made before and after the surgery.
Experimental groups
To investigate the impact of B1R and B2R genetic dele-
tion on pain behavior, three groups of mice were sub-
jected to closed fracture as described above: Group 1 
(wild-type WT mice, n = 9); Group 2 (B2KO, n = 9); 
Group 3 (B1KO, n = 9). All mice were tested before sur-
gery (baseline), 2 h, 4 h and 6 h after surgery, and then 
once daily during the first 7 postoperative days, and each 
week during the 4  weeks following the surgery. Pain 
behavior tests included mechanical stimulation, hot plate 
test and pain rating.
To assess the possible involvement of the COX path-
way, the effect of the COX-1/COX-2 inhibitor ketoprofen 
(50 mg/kg, s.c.), was tested in three additional groups of 
mice (n = 6) after production of a tibial closed fracture: 
Groups 4, 5 and 6 were WT, B1KO and B2KO treated 
with ketoprofen. In comparison, Groups 1, 2 and 3 were 
WT, B1KO and B2KO receiving a saline vehicle only. 
Pain behavior testing (mechanical stimulation, hot plate 
test, and pain rating) was performed before the surgery 
(T0 = baseline) and each 30  min up to 240  min after 
administration of ketoprofen or saline (administered at 
T0, just after basal assessment). The effect of ketoprofen 
administration was also assessed on behavioral testing 
on postoperative day 1 and 2 using the same procedure. 
Experiments were conducted following a double blind 
protocol.
To investigate the effect of pharmacological inhibition 
of B1R and B2R, WT mice subjected to a closed fracture 
were randomly assigned in four groups as follows: Group 
1 (n = 6) received the saline vehicle subcutaneously post-
operatively, Group 2 (n = 6) received the B2R antagonist 
HOE 140 (250  µg/kg subcutaneously) postoperatively, 
Group 3 (n = 6) received the B1R antagonist SSR 240612 
(10  mg/kg/oral) postoperatively and Group 4 (n = 6) 
received R954 (1 mg/kg subcutaneously) postoperatively. 
The doses of B1R and B2R antagonists used in this study 
were based on previous experiments of our groups [24, 
29]. SB-366791 [N-(3-methoxyphenyl)-4-chlorocinna-
mide], a potent and highly selective TRPV1 antagonist, 
was administered intraperitoneally at a dose of 1 mg/kg 
dissolved in 1% DMSO. Inhibitors (receptor antagonists, 
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COX inhibitors) or saline or 1% DMSO vehicle were 
administered at T0. Responses to mechanical, heat stim-
uli, and pain rating scale were determined every 30 min 
after T0 for 240  min, then 300, 480  min and 24  h after 
inhibitor administration. Experiments were conducted 
following a double blind protocol.
Kinin receptors mRNA expression using real time PCR 
(RT‑PCR)
Two days after surgery, mice (n = 6) were sacrificed 
(anesthesia overdose using pentobarbital) and both the 
fractured and contralateral non-fractured tibia were dis-
sected out. The RNA from both tibias was extracted from 
control mice, i.e. WT, B2KO and B1KO mice without 
fracture using kit RNAeasy kit (QIAGEN, S.A., Courta-
boeuf, France) according to the manufacturer’s instruc-
tions. Reverse transcription was performed using specific 
primer to mRNA of kinin B2R and B1R (Eurogentec, Bel-
gium). RT-PCR was performed in triplicate. Amplifica-
tion and detection were performed using an ABI PRISM 
7000 Sequence Detector system (Applied Biosystems, 
USA). 18S cDNA was amplified in parallel to normalize 
the expression levels of B1R and B2R mRNAs.
c‑Fos spinal cord immunohistochemistry
c-Fos immunohistochemistry was performed as previ-
ously described [28]. Mice were deeply anesthetized with 
pentobarbital 2 h after surgery and perfused transcardi-
ally with saline followed by 4% paraformaldehyde (PFA) 
using a peristaltic pump. Lumbar spinal cords were dis-
sected out and postfixed overnight at 4  °C in 4% PFA, 
then transferred into 30% (w/v) sucrose buffer for 48  h 
at 4  °C before freezing in isopentane. 20 µm thick coro-
nal sections were cut at the L3–L5 levels using a Microm 
Microtech cryostat (HM 500  M, Francheville, France). 
Sections were incubated with 0.3%  H2O2 in PBS for 
30 min at room temperature before exposure for 2 h to 
a PBS blocking solution containing 0.25% Triton X-100 
and 1.5% normal goat serum (Vector Laboratories, Burl-
ingame, CA, USA). Sections were then incubated with 
rabbit anti-c-Fos antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) diluted 1:20,000 in the same buffer 
for 48 h at 4 °C followed by biotinylated goat anti-rabbit 
antibody (Vector Laboratories) diluted 1:200 for 2  h at 
room temperature. After washing, sections were placed 
in horseradish peroxidase avidin-biotin complex (Vec-
tastain ABC kit, Vector Laboratories) diluted in PBS 
0.5% with Triton X-100 for 1  h at room temperature. 
Sections were finally stained in 3,3’-diaminobenzidine 
substrate kit (Vectastain DAB kit, Vector Laboratories) 
for 6  min and mounted on gelatin-coated slides. Sec-
tions were observed under a Nikon Eclipse 80i micro-
scope (Champigny sur Marne, France) and pictures of 
the area of interest were taken using a Nikon Digital Sight 
DS-5M-L1 camera and software under the 20× objec-
tive. Total number of c-Fos positive nuclei was quantified 
in superficial layers I and II of the L3–L5 spinal cord (6 
mice per condition, 3 sections per mouse) on thresholded 
images using the Image J software (NIH, USA).
Western blot analysis
B1R and B2R proteins were separated by SDS PAGE and 
analyzed by Western Blotting as previously described 
[23, 30]. Proteins were extracted using a lysis buffer con-
taining 10% glycerol, 20 mM Tris, 140 mM NaCl, 3 mM 
EDTA, protease and phosphatase inhibitor cocktails 
(Roche, Germany), and 1% Triton X-100. In agreement 
with the manufacturer (BD-Biosciences, USA) technical 
data sheet B2R receptor was revealed as a double band 
which was absent in the B2R deficient mice. The B1R 
polyclonal antibody was previously characterized in the 
laboratory [23].
Histology and immunohistochemistry
Tissue samples were fixed in 10% formalin and embedded 
in paraffin after fast decalcification (Decalcifier, Thermo 
shandon TBD1). Sections of 4–5 microns were made 
and stained with Haematoxylin Eosin for morphological 
study. Immunohistochemical studies were performed on 
histological sections from the same block, with the anti-
CD 68 antibody (Dako), which recognizes the monocyte/
macrophage (1/100, 30 min), anti CD-34 (Immunotech), 
which marks the vessels (1/100, 30 min) and anti CD 45 
(Dako), which indicates leukocytes (1/100, 30 min). The 
revelation was made by the avidin–biotin-peroxidase 
technique (LSAB kit).
Collagen deposition
The presence of collagen deposition was demonstrated 
by specific Syrius Red stainings, briefly, the sections were 
deparaffinized (3 toluene baths, 5  min) and then rehy-
drated by three successive baths of ethanol (100°, 95° and 
50°, 5 min) and a water bath (5 min). Sections were incu-
bated 30 min in a solution of Sirius Red (0.1% F3B satu-
rated picric acid) before being rinsed with water 5 min. 
The slides were observed under an optical microscope 
(Eclipse E400, Nikon) at a magnification ×2. Photographs 
(Microfire, Optronics) were analyzed using the 3.0 soft-
ware MorphoExpert to allow quantification of the surface 
measured by the collagen relative to the total area of tis-
sue fibrosis.
Statistical analysis
Since values for behavior were not normally distributed, 
they were subjected to nonparametric statistical analy-
sis. To assess whether the withdrawal responses changed 
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over time, Friedman’s test was used. When Friedman’s 
test was found significant (P < 0.05), pairwise compari-
sons were made using Wilcoxon’s signed rank test. Time 
point comparisons between groups were made using a 
nonparametric Kruskal–Wallis. When Kruskal–Wallis 
test was significant (P < 0.05), pairwise comparisons were 
made using Mann–Whitney U test.
The c-Fos results were expressed as mean ± SEM of the 
number of positive nuclei/section. Statistical analyses 
were performed using GraphPad Prism software (Graph-
Pad, San Diego, CA, USA). One-way ANOVA were 
followed by post-hoc multiple comparisons using Bonfer-
roni’s test.
Results
Throughout the experimental period, all mice remained 
well-groomed and maintained normal food and water 
intake. No change in body weight, no signs of spontane-
ous pain behavior, such as licking, biting, and flinching, 
were noticed after the surgery.
Fracture pain is blunted in the absence of kinin receptors
Baseline values for pain behavior parameters were not 
significantly different between groups before fracture 
induction (Fig.  1). Similarly, no behavioral modifica-
tion occurred in the non-fractured tibia mice (data not 
shown). After fracture, behavioral pain measurements 
were significantly but differently reduced both in B1KO 
and B2KO mice when compared to WT mice (Fig.  1). 
Maximal pain was observed in WT animals. In B1KO 
mice, both mechanical and thermal sensitivity were sig-
nificantly and persistently reduced from 2 h up to 7 days 
post fracture. In B2KO mice no difference was observed 
in mechanical sensitivity whereas thermal sensitivity 
was reduced to a similar level as that observed in B1KO. 
The subjective pain scale was significantly lower both 
in B1KO and B2KO mice when compared to WT mice 
from 2 h to 5 days. All mice recovered to control values 
2  weeks after fracture and no rebound in pain sensitiv-
ity was observed up to 4 weeks post-fracture. Concerning 
the locomotors function of the mice, no difference was 
found before the fracture or after the fracture concerning 
WT, B1KO and B2KO mice (Fig. 2).
Effect of absence of kinin receptors on c‑Fos induction 
during tibial fracture
c-Fos immunohistochemistry was performed to study the 
initial response to fracture in the dorsal horn of the spi-
nal cord in the three mouse strains. As shown in Fig. 3, 
2  h after tibial fracture there was a significant increase 
in c-Fos immunoreactivity in the superficial layers of the 
ipsilateral L3–L5 dorsal horn of WT mice compared to 
sham animals and to the contralateral side. The number 
of c-Fos positive nuclei was similar to WT in fractured 
B1KO mice whereas it was significantly reduced in B2KO 
fractured mice.
Kinin receptors mRNA and protein expression
In WT mice, B1R and B2R mRNA levels in the tibia 
were significantly increased at 2 days after fracture when 
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Fig. 1 Mechanical (a), thermal (b) hyperalgesia and subjective 
pain (c) caused by fractured tibia are reduced in B1 and B2 receptor 
knockout (B1KO, B2KO) compared to wild‑type (WT) mice. After 
baseline testing, male adult mice were subjected to closed tibial 
fracture and tested for paw withdrawal threshold to evaluate 
mechanical sensitivity (a) or paw withdrawal latency to evaluate 
thermal sensitivity (b). Subjective pain (c) was expressed by a rating 
scale from 1 to 5 as described in “Materials and methods” section. 
The contralateral side was also tested at each time point for each 
group of mice: the mechanical thresholds were 8 g (cut off ), the heat 
latencies were 12 s (cut off ), and the subjective pain scores were zero 
in all groups at all time points. Each bar represents mean ± SEM of 9 
mice per group. Data were subjected to Friedman’s test followed by 
Wilcoxon’s signed rank test. *P < 0.05 when comparing B1KO to WT. 
#P < 0.05 when comparing B2K0 to WT
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compared to the non-fractured contralateral side and 
control mice (Fig.  4). In B1KO and B2KO mice, basal 
expression of the remaining receptor (B2R and B1R, 
respectively) was significantly higher than in WT. In 
addition, as in WT mice, B2R (in B1KO) and B1R (in 
B2KO) mRNA levels were significantly increased in the 
fractured side when compared to both the non-fractured 
side and control mice.
As shown in Fig.  5, an increase in B1R and B2R was 
evidenced in the extracts obtained from tissue surround-
ing the site of fracture (hematoma), thus corroborating 
mRNA data. However, no change in B1R or B2R protein 
expression could be detected by Western blot in frac-
tured bone, paw skin extracts, and in total extracts of L3–
L5 spinal cord of injured mice (data not shown).
Pharmacological inhibition of kinin receptors reduced 
fracture pain
Before induction of fracture, different groups of WT mice 
were treated with either a B2R antagonist or two distinct 
B1R antagonists. Withdrawal threshold to mechanical 
0
200
400
600
WT
WT Fracture
B1KO Fracture
B1KO
B2KO
B2KO Fracture
To
ta
l a
ct
iv
ity
 (c
ou
nt
s)
Fig. 2 Locomotors activity. Overall locomotors activity was recorded 
by an actimeter preoperatively and postoperatively. Locomotors 
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Fig. 4 B1 and B2 receptor mRNA expression is maximal at the site of 
fracture. Two days after fracture, mice were sacrificed and RNA was 
extracted from the fractured (F) and contralateral (CL) non‑fractured 
limbs. RNA was also extracted from control (C) mice without fracture 
(i.e. WTC or B2KOC, B1KOC mice). Each bar represents mean ± SEM 
of at least 6 mice per group, Data were subjected to Wilcoxon signed 
rank test. *P < 0.05 compared to ipsilateral fractured WT
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stimulation (Fig.  6a) and withdrawal latency to thermal 
stimulation (Fig. 6b) increased transiently after adminis-
tration of B2R or B1R antagonists. Blockade of B1R and 
B2R with SSR240612 and HOE 140 induced a signifi-
cant reduction of fracture pain, which lasted up to 4  h. 
The subjective pain scale (Fig.  6c) was also significantly 
reduced for up to 4 h following SSR240612 and HOE 140 
administration. Blockade of B1R with the R954 antago-
nist was also efficient but the inhibition of pain behavior 
was more transient with a maximum efficacy peaking 
at around 1  h post-administration. Surprisingly, after 
this initial analgesic phase, R954 increased significantly 
pain sensitivity above saline values both on thermal pain 
(1  day post-injection) and subjective pain (between 4  h 
and 1 day after injection).
Inhibition of COX‑1/COX‑2 had no effect on fracture pain 
in the absence of kinin receptors
In WT mice, withdrawal threshold to mechanical stim-
ulation (Fig.  7a) and withdrawal latency to thermal 
stimulation (Fig.  7d) were increased transiently after 
ketoprofen administration compared to saline and the 
effect lasted between 120 and 240  min depending on 
the test. Subjective pain was also transiently reduced 
(Fig.  7g). In contrast, ketoprofen had no effect on the 
residual mechanical and thermal sensitivity observed in 
B1KO (Fig. 7b, e, h) and B2KO (Fig. 7c, f, i) mice.
Inhibition of TRPV1 still reduced fracture pain 
in the absence of kinin receptors
In WT mice, withdrawal threshold to mechanical stimu-
lation (Fig. 8a) and withdrawal latency to thermal stimu-
lation (Fig.  8d) were significantly but transiently (up to 
8 h) increased after treatment with the TRPV1 antagonist 
(SB366791) in comparison with saline. Subjective pain 
was also transiently reduced (Fig.  8g). Importantly, the 
TRPV1 antagonist still reduced significantly mechanical 
and thermal sensitivity in B1KO (Fig.  8b, e) and B2KO 
(Fig. 8c, f ) mice.
Histology and immunohistochemistry
There is no visible morphological difference in B2KO 
and B1KO mice when compared to wild type mice before 
fracture (Fig. 9a, d and g). Four weeks after the fracture, 
we note the presence of fibrosis, which shows no sig-
nificant morphological differences between B1KO and 
B2KO when compared to wild-type mice (Fig. 9b, e and 
h).
There was no difference between groups with respect 
to the expression of markers of vessels (CD34) or leuko-
cyte (CD 45) (data not shown). However, an increase in 
the expression of osteoclast marker (CD 68) was found in 
all groups after the fracture when compared to its expres-
sion before the fracture. There was no significant differ-
ence between groups regarding the expression of CD 68 
(data not shown).
Fig. 5 Bradykinin receptor and protein expression. B1‑kinin receptor (B1R) and B2‑kinin receptor (B2R) expression was analyzed by Western 
blotting. Protein extracts were obtained from wild control type mice (WT) and from mice with tibial fracture, samples from the fractured side (F) and 
contralateral non‑fractured (NF) side were analyzed. Proteins extracts from hematoma were compared. Tissue sample from B1R and B2R deficient 
mice were used to check the antibody specificity. The specific of both B1R and B2R antibodies was attested by the absence of protein obtained 
from B1R and B2R KO mice. Qualitative differences in protein expression of B1R and B2R were shown and were further quantified by densitometry. 
Results shown in bar graphs are presented as arbitrary units by comparison to expression in WT taken as control. *P < 0.01 when compared to 
expression in WT
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Collagen deposition
An increased expression of collagen was found in the dif-
ferent groups after the fracture, no significant difference 
between groups was found (data not shown).
Discussion
In the recent years, knowledge of the signaling pathways 
involved in chronic post-fracture pain has tremendously 
improved. The involvement of nerve growth factor and 
inflammatory cytokines and mediators has been care-
fully described using closed fracture model in rats [31]. 
Because of the recent availability of genetically modified 
mice, we have developed a fracture pain model in mice 
[10] which opens new possibilities to investigate physi-
opathological mechanisms [32]. In the present study, 
we describe for the first time that the absence of B1R or 
B2R reduces acute post-fracture pain. The data are con-
sistent with the role of B1R and B2R in pain sensitization 
in inflammatory models. To confirm the involvement 
of B1R and B2R in acute fracture pain, we also demon-
strated that pharmacological blockade with specific B1R 
or B2R antagonists significantly reduces post-fracture 
pain. Moreover, the pain mediated by these receptors is 
dependent on the COX signaling pathways as the COX-1/
COX-2 inhibitor ketoprofen had no analgesic effect in 
the absence of B1R or B2R. By contrast, TRPV1, another 
important signaling pathway [5, 33] that conveys painful 
stimuli and is likely involved in post-fracture pain, appears 
to be partly independent of B1R and B2R activation.
Kinins are released in damaged tissues from circulat-
ing kininogen precursors by kallikreins and mediate rapid 
algogenic and pro-inflammatory effects. The involvement 
of B1R and B2R in inflammatory reaction and thereby in 
pain mechanism is documented in different pain models 
[5]. In knockout mice lacking both B1R and B2R, baseline 
nociceptive responses to heat and nociceptive responses 
to BK were abolished in acute acetic acid-induced vis-
ceral nociception while heat hypersensitivity in carra-
geenan induced paw inflammation was strongly reduced, 
although chronic inflammatory or nerve injury responses 
were unaltered [34]. In addition, the distinct role of each 
receptor can be explored by using specific antagonists and 
single receptor KO animals. Deletion of B2R, or treatment 
with a B2R antagonist, also abolished the nociceptive 
responses to intraplantar infusion of carrageenan indicat-
ing that B2R activation is an essential step in the initiation 
of the nociceptive response [7, 35]. Deletion of B2R and 
B2R receptor antagonist also prevented opioid-induced 
hyperalgesia confirming an important nociceptive role of 
the B2R [36]. In contrast, B1 agonists could not directly 
activate primary afferent neurons in a spinal nociceptive 
reflex preparation [37] or in dorsal root ganglions [38]. 
Therefore, it is likely that activation of the B2R rather that 
B1R is required to mediate the direct algogenic effect of 
BK in acute pain. This is consistent with the localization 
of B2R on sensory neurons and the ability of B2R antago-
nists to inhibit BK-induced nociception [40–41]. These 
data also suggested that although B1R are not involved in 
the initial algogenic effect, they contribute to inflamma-
tory hyperalgesia secondary to acute pain.
Our data are consistent with these differential effects of 
B1R and B2R. First, the absence of B1R did not reduce 
c-Fos expression in the superficial layers of the spinal 
cord 2  h after the fracture whereas fracture-induced 
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Fig. 6 B1 and B2 receptor antagonists reduce mechanical (a), 
thermal (b) sensitivities and subjective pain (c) on the fractured 
tibia side in wild‑type (WT) mice. Experiments were conducted as 
described in Fig. 1. At time 0, the B2 receptor antagonist Icatibant 
(HOE 140) was given as a single subcutaneous injection (250 µg/kg). 
B1 receptor antagonists were given either as gavage using SSR240612 
(10 mg/kg body weight) or as a single subcutaneous injection of 
R954 (10 mg/kg body weight). Behaviors were recorded for 8 h and 
then once the subsequent day 24 h after drug administration. Each 
bar represents mean ± SEM of 6 mice per group. B: baseline. Data 
were subjected to Friedman’s test followed by Wilcoxon’ signed rank 
test. *, # and €P < 0.05 compared with saline‑treated WT mice
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neuronal activation was reduced in B2KO. Consider-
ing the time course of this immediate early gene induc-
tion, this result suggests that B1R is not involved in the 
acute generation of fracture pain, possibly because B1R 
might not be located directly on sensory neurons but on 
surrounding tissue. Second, inflammation appears to be 
a prerequisite to ensure B1R induction and subsequent 
activation, as demonstrated here by RT-PCR and West-
ern Blotting. These analyses showed that expression of 
B1R and B2R increased only in the tissue around the frac-
ture. No protein over-expression could be detected either 
in the bone or in the L3–5 spinal cord segments or in the 
plantar skin of the paw. Taken together, this information 
does not support the expression of B1 receptors on sen-
sory fibers but rather suggest that up regulation of these 
BK receptors occurs on infiltrating inflammatory cells 
(macrophages and leucocytes). Therefore the analgesic 
mechanism of B1R antagonists appears rather indirectly 
mediated likely by blunting the inflammatory response 
of infiltrating cells. The assumption of an indirect effect 
of the antagonists is also consistent with the efficiency of 
R954. R954 is a potent, selective and stable B1R antago-
nist with only peripheral action [42]. The distribution of 
R954 assessed by binding studies is restricted to periph-
eral tissues (liver, lung kidney) and hematological fluids 
with a very slow metabolizing rate over 24  h. Interest-
ingly, this recent work also demonstrated that R954 is 
unable to cross the blood brain barrier and thus may 
not affect pain arising from central nervous structures. 
In the case of B2R, basal expression was detected in the 
skin and spinal cord. In addition to a possible action on 
inflammatory cells, the analgesic effect of HOE 140 could 
thus be exerted directly on sensory fibers.
Previous studies have demonstrated a role for B2R 
signaling in various animal pain models [5, 40]. In our 
study, we found that thermal hyperalgesia and subjective 
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Fig. 7 COX inhibition with ketoprofen (K) reduces pain sensitivities in wild‑type (WT) mice but has no effect in B1 and B2 receptor knockout (B1KO, 
B2KO) mice. WT, B1KO and B2KO were subjected to tibial fracture and received a single injection of K (50 mg/kg body weight) at time 0. Behaviors 
were recorded during 4 h. Each bar represents mean ± SEM of 6 mice per group. Data were subjected to Friedman’s test followed by Wilcoxon 
signed rank test. *P < 0.05 compared with fractured untreated WT
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pain quotation were diminished in KOB2 fractured mice, 
but mechanical hyperalgesia was not affected. These 
results are consistent with prior studies that observed 
BK signaling contributed to heat but not mechani-
cal hyperalgesia in animal pain models [43–46] and 
in humans [47]. In the present study, three behavioral 
tests indicate that acute treatment with either B1 or B2 
antagonist reduced post-fracture pain in WT mice. As 
B1 receptor is not detectable in non-fractured WT mice 
and appeared specifically expressed in the fracture area, 
inhibition of B1R may be a potential therapeutic target 
for reducing fracture pain.
Interestingly, in the absence of B1R or B2R, inhibition 
of COX-1/COX-2 did not further reduce mechanical and 
thermal nociception. This observation is consistent with 
the induction of COX-2 following B1R and B2R activa-
tion as previously established [48, 49].
It has been proposed that TRPV1 activation is the final 
step in BK-induced heat sensitization [5, 50, 51]. The 
TRPV1 antagonist SB366791 did reduce post-fracture 
heat and mechanical hyperalgesia and subjective pain 
behavior in WT fractured mice, but this effect was not 
lost in the B1KO and B2KO mice indicating that TRPV1 
involvement was not restricted to BK induced post-frac-
tured hyperalgesia and pain behavior.
Conclusion
This study utilized a genetic and pharmacologic approach 
to demonstrate that both kinin receptors (B1R and B2R) 
contribute to acute post-fracture pain through a down-
stream COX-1/COX-2 mechanism. These results suggest 
that blocking B1R and B2R signaling may be an effective 
therapeutic approach in the management of post-fracture 
pain.
Fig. 8 TRPV1 inhibition reduces pain sensitivities in wild‑type (WT) and B1 and B2 receptor knockout (B1KO, B2KO) mice. WT, B1KO and B2KO mice 
were subjected to tibial fracture and received a single injection of SB 366791 (1 mg/kg) at time 0. Behaviors were recorded during 8 h and the 
subsequent day. Each bar represents mean ± SEM of 6 mice per group. Data were subjected to Friedman’s test followed by Wilcoxon signed rank 
test. *P < 0.05 compared with fractured untreated, i.e. WT, B1KO and B2KO + saline or + DMSO respectively
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